|

Belantamab mafodotin Clinical Trials

11 actively recruiting trials across 10 locations

▲ +1 trial since June 2026

Also known as: BLENREP, Belantamab Mafodotin-blmf, Blenrep, GSK2857916, J6M0-mcMMAF

Pipeline

Phase 1: 1Phase 2: 6Phase 3: 1Phase 1/2: 3

Top Sponsors

  • GlaxoSmithKline3
  • M.D. Anderson Cancer Center2
  • University of Chicago1
  • Mayo Clinic1
  • Massachusetts General Hospital1

Indications

  • Cancer11
  • Multiple Myeloma6
  • Refractory Multiple Myeloma3
  • Recurrent Multiple Myeloma2
  • Newly Diagnosed Multiple Myeloma1

Houston, Texas2 trials

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

M D Anderson Cancer Center

Phase 1
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

MD Anderson Cancer Center

Phase 2

Mobile, Alabama1 trial

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

GSK Investigational Site

Phase 3

Bullhead City, Arizona1 trial

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

GSK Investigational Site

Phase 1/2

Gilbert, Arizona1 trial

Selinexor and Backbone Treatments of Multiple Myeloma Patients

Banner MD Anderson Cancer Center

Phase 1/2

Los Alamitos, California1 trial

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

GSK Investigational Site

Phase 2

Jacksonville, Florida1 trial

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

Mayo Clinic in Florida

Phase 2

Atlanta, Georgia1 trial

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

Emory University/Winship Cancer Institute

Phase 2

Chicago, Illinois1 trial

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

University of Chicago Medicine Comprehensive Cancer Center

Phase 2

Ames, Iowa1 trial

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

Mary Greeley Medical Center

Phase 1/2

Boston, Massachusetts1 trial

Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma

Massachusetts General Hospital

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.